hnps-PLA Inhibitor

CAS No. 185298-58-2

hnps-PLA Inhibitor( hnps-PLA Inhibitor | MDK-8582 | MDK 8582 )

Catalog No. M17396 CAS No. 185298-58-2

Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 67 In Stock
5MG 110 In Stock
10MG 192 In Stock
25MG 323 In Stock
50MG 482 In Stock
100MG 687 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    hnps-PLA Inhibitor
  • Note
    Research use only, not for human use.
  • Brief Description
    Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).
  • Description
    MDK-8582, also known as Hnps-PLA Inhibitor, is an nhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA). The best one inhibited hnps-PLA(2) and LTA(4)H-h with IC(50) values of 9.2 ± 0.5 μM and 2.4 ± 1.4 μM, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    hnps-PLA Inhibitor | MDK-8582 | MDK 8582
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    LTA(4)H-h| hnsPLA2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    185298-58-2
  • Formula Weight
    379.42
  • Molecular Formula
    C21H21N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)N)ccc2
  • Chemical Name
    2-(4-(2-Amino-2-oxoethoxy)-1-benzyl-2-ethyl-1H-indol-3-yl)-2-oxoacetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Meng H, Liu Y, Zhai Y, Lai L. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase. Eur J Med Chem. 2013 Jan;59:160-7
molnova catalog
related products
  • ML348

    ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM).

  • SU4984

    SU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).

  • Dovitinib

    A novel, multitargeted RTK inhibitor of class III, IV, and V RTKs.